Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 1,866 Shares

Natera, Inc. (NASDAQ:NTRA - Get Free Report) CFO Michael Burkes Brophy sold 1,866 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $93.97, for a total value of $175,348.02. Following the completion of the sale, the chief financial officer now directly owns 67,542 shares of the company's stock, valued at $6,346,921.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Michael Burkes Brophy also recently made the following trade(s):

• On Monday, April 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The shares were sold at an average price of $93.14, for a total transaction of $115,307.32.
• On Thursday, April 25th, Michael Burkes Brophy sold 705 shares of Natera stock. The shares were sold at an average price of $89.55, for a total transaction of $63,132.75.
• On Tuesday, April 23rd, Michael Burkes Brophy sold 1,523 shares of Natera stock. The stock was sold at an average price of $91.38, for a total transaction of $139,171.74.
• On Tuesday, April 2nd, Michael Burkes Brophy sold 1,378 shares of Natera stock. The shares were sold at an average price of $92.62, for a total value of $127,630.36.
• On Thursday, March 28th, Michael Burkes Brophy sold 914 shares of Natera stock. The shares were sold at an average price of $90.42, for a total value of $82,643.88.
• On Tuesday, March 5th, Michael Burkes Brophy sold 2,826 shares of Natera stock. The stock was sold at an average price of $88.36, for a total value of $249,705.36.
• On Tuesday, February 6th, Michael Burkes Brophy sold 34,029 shares of Natera stock. The shares were sold at an average price of $70.03, for a total transaction of $2,383,050.87.

Natera Stock Up 3.5 %

NASDAQ:NTRA traded up $3.26 during trading hours on Friday, hitting $96.98. The stock had a trading volume of 1,069,756 shares, compared to its average volume of 1,417,820. The company has a market cap of $11.86 billion, a PE ratio of -25.59 and a beta of 1.38. The business has a 50 day simple moving average of $90.56 and a two-hundred day simple moving average of $69.29. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $98.82. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37.

Natera (NASDAQ:NTRA - Get Free Report) last issued its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, beating analysts' consensus estimates of ($0.73) by $0.09. The firm had revenue of $311.11 million during the quarter, compared to analyst estimates of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. Analysts predict that Natera, Inc. will post -2.35 EPS for the current year.

Institutional Investors Weigh In On Natera

A number of institutional investors have recently modified their holdings of NTRA. Chevy Chase Trust Holdings LLC bought a new stake in Natera during the first quarter valued at $14,467,000. GSA Capital Partners LLP grew its holdings in shares of Natera by 41.8% during the first quarter. GSA Capital Partners LLP now owns 28,222 shares of the medical research company's stock valued at $2,581,000 after purchasing an additional 8,319 shares during the last quarter. RiverPark Advisors LLC raised its position in shares of Natera by 581.8% during the 1st quarter. RiverPark Advisors LLC now owns 2,952 shares of the medical research company's stock worth $270,000 after purchasing an additional 2,519 shares during the period. Nikko Asset Management Americas Inc. acquired a new position in Natera during the 1st quarter valued at approximately $33,938,000. Finally, Jennison Associates LLC increased its position in Natera by 121.9% in the first quarter. Jennison Associates LLC now owns 472,147 shares of the medical research company's stock worth $43,183,000 after buying an additional 259,336 shares during the period. Institutional investors and hedge funds own 99.90% of the company's stock.

Wall Street Analyst Weigh In

NTRA has been the topic of several analyst reports. StockNews.com raised shares of Natera from a "sell" rating to a "hold" rating in a report on Wednesday. Stephens reissued an "overweight" rating and issued a $78.00 price target on shares of Natera in a report on Tuesday, January 30th. Piper Sandler upped their price objective on Natera from $70.00 to $110.00 and gave the stock an "overweight" rating in a report on Wednesday, March 6th. Raymond James downgraded Natera from a "strong-buy" rating to an "outperform" rating and raised their target price for the company from $68.00 to $85.00 in a report on Tuesday, February 20th. Finally, Sanford C. Bernstein upgraded shares of Natera from a "market perform" rating to an "outperform" rating and set a $120.00 price target for the company in a report on Friday, April 5th. One research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $86.40.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.